Arvinas, Inc. (ARVN) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-24
Business type: Asset play
How it makes money
It currently generates no product revenue, relying entirely on sporadic upfront payments and milestones from strategic pharmaceutical collaboration agreements.
As a clinical-stage biotechnology firm, it has yet to commercialize any therapeutic products. Revenue is strictly limited to research collaborations where partners pay for the potential to access its proprietary protein degradation technology. Profitability remains dependent on the future successful regulatory approval and sale of drug candidates currently in development.
What protects it: the moat
Management claims its proprietary protein degradation platform and intellectual property portfolio create a barrier against competitors in the drug development space.
The company asserts that its 'PROTAC Discovery Engine' is a novel modality capable of addressing 'undruggable' proteins that traditional therapies cannot reach. Its competitive moat relies heavily on its ability to obtain and defend patents covering these specific therapeutic mechanisms.
What could damage it
Failure to receive regulatory approval for its drug candidates would permanently destroy its ability to generate revenue and sustain operations.
The business model depends on successfully navigating the clinical trial process. If the FDA or similar authorities reject its applications, the company loses the primary output of its investment, forcing it to cease operations as it has no existing commercial products to provide a financial cushion.
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.